Loading...
•
Jun 30, 2023
Centessa Q2 2023 Earnings Report
Reported financial results and business highlights.
Key Takeaways
Centessa Pharmaceuticals reported its financial results for the second quarter ended June 30, 2023. The company's cash, cash equivalents, and short-term investments totaled $303.6 million as of June 30, 2023, with a net loss attributable to ordinary shareholders of $24.9 million for the second quarter.
Enrollment and dosing ongoing in registrational study of SerpinPC for the treatment of hemophilia B
Enrollment and dosing ongoing in Phase 1/2a Study of LB101, a PD-L1xCD47 LockBody® for the treatment of solid tumors
IND-enabling activities advancing for ORX750, an oral selective orexin receptor 2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders
Nominated second LockBody candidate, LB206, a conditionally bivalent PD-L1xCD3 bispecific monoclonal antibody
Centessa
Centessa
Forward Guidance
Centessa Pharmaceuticals has line of sight to multiple potential clinical milestones expected over the next several quarters and with a cash runway into 2026, they believe they are well positioned to advance their pipeline of potentially transformative medicines and deliver value for their stakeholders.